GSK opted out of WAVE's AATD program, citing a small market. However, with ~200,000 patients, this is a large rare disease. The decision, made before data, likely reflects a portfolio reprioritization under a new CEO, not a fundamental issue with the asset's commercial potential.

When facing a crisis, Fibrogen's CEO decided to shut down discovery research programs. The value inflection opportunity was too far in the future, and capital was better spent on assets with the potential to create more near-term value, ensuring the company's survival.

Sanofi announced three significant collaborations in just one week with Indupro, Adel, and Drenbio. This rapid-fire deal-making underscores a concentrated strategic effort to build a leading pipeline in autoimmune and neurodegenerative diseases by acquiring innovative, early-stage assets like bispecific antibodies and tau-targeting MABs.

Under new CEO Luke Meals, GSK is implementing a strategy of fiscal tightening combined with aggressive pipeline investment. The company plans to cut $2.5 billion in costs while doubling its planned Phase 3 trial starts from 10 to 20 this year. This approach aims to fuel long-term growth and meet a $53.2B sales target by 2031 while navigating a major patent cliff.

Despite familiar names topping the rankings, R&D spending is down across most of big pharma, with major players like Bristol Myers Squibb, Pfizer, and Merck all reducing budgets. This marks a significant reversal after three decades of consecutive increases in industry-wide drug development pipelines.

Strategic investors like Sanofi and AbbVie invest in early-stage biotechs not just for financial return, but to monitor disruptive technologies. This gives them a seat at the table to observe innovations that could render their own multi-billion dollar franchises obsolete in the next decade.

Discontinued drugs aren't hard to identify; the real challenge is navigating the out-licensing process inside a large pharma company. Without an internal champion to drive the complex approvals for a non-priority asset, promising drugs can languish on the shelf due to corporate inertia, not a desire to hide them.

With over 5,000 oncology drugs in development and a 9-out-of-10 failure rate, the current model of running large, sequential clinical trials is not viable. New diagnostic platforms are essential to select drugs and patient populations more intelligently and much earlier in the process.

A drug that is proven safe in humans but fails to show efficacy for its initial target is not a total loss. It's a de-risked asset with a known safety profile, making it a prime, low-risk candidate for repurposing into a new disease area, especially for rare diseases with orphan drug protections.